

Provided by:



## Acute Leukemia and Myeloid Neoplasms Case Conference 2025-2026

**Acute Leukemia and Myeloid Neoplasms Case Conference 2025-2026 - 5/27/2026**

**May 27, 2026**

**12:00 PM - 1:00 PM**

**Perelman Center for Advanced Medicine, Conference Room 12-122**

### Target Audience

This program has been designed for DIAGNOSTIC RADIOLOGY, INTERNAL MEDICINE - Medical Oncology, PATHOLOGY - CLINICAL, PEDIATRICS - Pediatric Hematology-Oncology

### Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss the importance of adequate marrow cellularity. Tracking technique of marrow.
- 2 Review the standard of care treatment, medications, concomitant medications, risks, benefits and potential toxicities or how to find out/whom to ask.
- 3 Discuss appropriate prophylactic therapies required for patients receiving therapy for acute leukemia.
- 4 Discuss pathology diagnostic reports in correlation of clinical variables into pathology interpretations of clinical specimens.

### Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Designation of Credit:

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ABIM MOC:** up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**ABPath MOC:** up to 1 MOC points

**Nurses:** This activity is for 1.00 contact hours.

**Pharmacists:** This activity is approved for 1.00 contact hours UAN Number: JA0000324-0000-26-028-L04-P

For more information, please contact  
Julie Mcdaniel, Xing Lor, Michele Bloovman, Hailey Gallone  
(267) 970-8367, (215) 662-3181, (215) 662-3191, (215) 220-9726  
mcdjulie@upenn.edu, xing.lor@penntmedicine.upenn.edu,  
michele.bloovman@penntmedicine.upenn.edu, hgallone@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

**PAs:** Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support\*:** None

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Adam Bagg, MD	Other Planning Committee Member	Consulting Fee-Scopio   Speakers Bureau-Recordati - 06/03/2025
Martin Carroll, MD	Other Planning Committee Member	Nothing to disclose - 04/21/2026
Alison Carulli, PharmD	Pharmacy Planner	Nothing to disclose - 12/19/2025
Noelle V. Frey, MD, MSCE	Other Planning Committee Member	Consulting Fee-Kite Pharma   Consulting Fee-Autolus - 08/28/2025
Saar Gill, MD	Other Planning Committee Member	Grant or research support-Novartis / Amgen   Advisor-Interius Biotherapeutics (Relationship has ended)   Advisor-Carisma Therapeutics (Relationship has ended)   Advisor-AvenCell - 10/21/2025
Elizabeth Hexner, MD	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Blueprint Medicines   Advisor-Cabaletta Bio Inc   Advisor-Disc Medicine   Membership on Advisory Committees or Review Panels, Board Membership, etc.-American Board of Internal Medicine - 09/09/2025
Kimberly A Hummel, BSN, RN	Other Planning Committee Member	Nothing to disclose - 09/30/2025
Putzer Hung, MD, PhD	Other Planning Committee Member	Nothing to disclose - 09/30/2025
Ximena J Jordan Bruno, MD	Other Planning Committee Member	Nothing to disclose - 09/19/2025
Colleen R Kucharczuk, CRNP RN	Nurse Planner	Nothing to disclose - 07/03/2025

Catherine Lai, MD, MPH	Other Planning Committee Member	Advisor-Genentech   Advisor-Servier   Advisor-Syndax   Grant or research support-Bristol-Myers Squibb   Grant or research support-Jazz Pharma   Advisor-Kura   Advisor-Arcellx (Relationship has ended)   Advisor-Rigel   Advisor-AbbVie, Inc.   Advisor-Novartis (Relationship has ended)   Consulting Fee-Jazz Pharma (Relationship has ended)   Consulting Fee-PDS Biotechnology   Consulting Fee-Astellas   Advisor-Daiichi (Relationship has ended) - 03/06/2026
Selina Luger, MD	Other Planning Committee Member	Consulting Fee-Novartis (Advanced Health Media) (Relationship has ended)   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astra Zeneca Pharmaceuticals   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Marker   Membership on Advisory Committees or Review Panels, Board Membership, etc.-daichi sankyo   Membership on Advisory Committees or Review Panels, Board Membership, etc.-astellas (Relationship has ended)   Consulting Fee-marker therapeutics (Relationship has ended) - 10/03/2025
Mary Ellen Martin, MD	Other Planning Committee Member	Nothing to disclose - 04/30/2026
Andrew H Matthews, MD	Co-Director, Faculty	Nothing to disclose - 01/05/2026
Shannon R. McCurdy, MD	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Sanofi Genzyme   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Geron   Grant or research support-Sanofi Genzyme - 04/21/2026
Jennifer Morrissette, PhD	Other Planning Committee Member	Advisor-AbbVie, Inc. (Relationship has ended)   Stocks or stock options, excluding diversified mutual funds of a publicly traded company-ThermoFisher   Stocks or stock options, excluding diversified mutual funds of a publicly traded company-AbbVie, Inc.   Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Johnson & Johnson   Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Pfizer, Inc. - 08/06/2025
Alexander E Perl, MD	Other Planning Committee Member	Consulting Fee-AbbVie, Inc. (Relationship has ended)   Advisor-Stemline (Relationship has ended)   Advisor-Johnson & Johnson (Relationship has ended)   Advisor-Schrodinger (Relationship has ended)   Advisor-Aptose (Relationship has ended)   Advisor-Curis (Relationship has ended)   Advisor-Rigel (Relationship has

		ended)  Advisor-Immunogen (Relationship has ended)  Advisor-Actinium (Relationship has ended)  Consulting Fee-Astellas  Consulting Fee-Foghorn  Advisor-Bristol-Myers Squibb (Relationship has ended)  Advisor-Genentech (Relationship has ended)  Consulting Fee-Daiichi Sankyo  Consulting Fee-Syndax  Consulting Fee-LLS-BeatAML LLC  Grant or research support-AbbVie, Inc.  Grant or research support-Astellas  Grant or research support-Daiichi Sankyo  Grant or research support-Syndax  Grant or research support-FujiFilm (Relationship has ended) - 10/07/2025
Linda Perry, MS, PA-C	Physician Assistant Planner	Paid consultant-Kadmon   Speakers Bureau-Sanofi Genzyme  Paid consultant-Incyte Corporation  Speakers Bureau-Incyte Corporation - 10/03/2025
Olga Pozdnyakova, MD, PhD	Other Planning Committee Member	Advisor-Scopio  Consulting Fee-GBA Pharma U.S. Inc. (Relationship has ended)  Advisor-Sysmex  Advisor-hema.to  Paid consultant-Beckman Coulter  Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Pheno.ta - 06/16/2025
Keith Pratz, MD	Course Director	Advisor-AbbVie, Inc.  Advisor-Bristol-Myers Squibb (Relationship has ended)  Advisor-Novartis / Amgen (Relationship has ended)  Advisor-Jazz Pharmaceuticals (Relationship has ended)  Advisor-Astellas (Relationship has ended)  Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended)  Advisor-Roche (Relationship has ended) - 03/18/2026
Jacqueline Smith, CRNP	Other Planning Committee Member	Nothing to disclose - 09/02/2025

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected